Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Serum plasma" patented technology

Thermo-responsive polymer-based method and diagnostic kit for the extraction, enrichment, and detection of HCV antigens via specific antibody conjugation

PCT designated stageWO2026149630A1Smart polymerColloidal au
A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

Use of reagent for detecting ILA concentration in preparation of product for predicting curative effect of esophageal squamous cell carcinoma immunotherapy, prediction method and equipment

ActiveCN121856550BComponent separationStage I Esophageal Squamous Cell CarcinomaOncology
The application discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting the curative effect of esophageal squamous cell carcinoma immunotherapy, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. The reagent for detecting indole-3-lactic acid concentration is aimed at samples selected from serum, plasma, blood, tumor tissue or fecal samples. By establishing a prediction model for the curative effect of esophageal squamous cell carcinoma immunotherapy, the curative effect of immunotherapy on esophageal squamous cell carcinoma patients can be accurately predicted, valuable reference bases can be provided for clinicians, thus helping to formulate individualized immunotherapy strategies and improving the curative effect of immunotherapy.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Platelet antibody detection and cross matching blocking layer chromatography kit and detection method thereof

PendingCN122259878ARetain natural structural integrityHigh recovery rateBiological testingImmune complex depositionBlood plasma
The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI +1

A material for detecting serum plasma antibodies to nicotinic acetylcholine receptors and methods of use thereof

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.
Owner:TAIZHEN (JIANGSU) MEDICAL TESTING LABORATORY CO LTD

A Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry

PendingCN122307101AAntigenBlood markers
This invention discloses a Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry, belonging to the field of clinical immunology testing. It includes solutions R1 and R2. Solution R1 is a dispersion of double-coupled latex microspheres coated with natural Mycoplasma pneumoniae antigens, and solution R2 is a sample diluent containing an enhancer. The test samples can be serum, plasma, or whole blood samples, and it is applicable to biochemical analyzers, protein analyzers, or combined blood cell and immunoturbidimetric analyzers. The kit prepared by this invention can be used on various instruments, has a wide range of detection targets, and can be coupled with other instruments to detect various clinically valuable blood indicators, further shortening the testing time. It solves the problems of poor accuracy, low efficiency, and limited application scenarios caused by the subjective interpretation of results, long processing time, and limited applicability of blood samples in existing technologies. It can effectively simplify the testing process and improve diagnostic efficiency.
Owner:CHONGQING ZHONGMEI ZHONGYI BIOENGINEERING CO LTD